Glucagon-like peptide-1 receptor agonist (GLP-1RA) medications have transformed the treatment of type 2 diabetes and obesity, with associated reductions in cardiovascular and nephrological complications.1,2 Semaglutide and tirzepatide are second-generation GLP-1RA medications approved by the Food and Drug Administration for the treatment of diabetes and obesity.3,4,5,6 The main associated adverse outcomes are gastrointestinal outcomes, including nausea, vomiting, diarrhea, gastroparesis, and constipation. Here, GLP1R is linked to Obesity.